News

NanoGroup S.A. has published an Exemption Document in connection with the offering of Series O shares for the purposes of a transaction with Auxilius Pharma S.A.

On September 23, 2026, NanoGroup S.A. published an Exemption Document regarding an offering of up to 25,997,977 new Series O common bearer shares…

“BUY” Recommendation for NanoGroup S.A.

“BUY” Recommendation for NanoGroup S.A. On 17 September 2026, Dom Maklerski INC S.A. issued a “BUY” recommendation for NanoGroup S.A. The target price…

NanoGroup at the 17th Congress of the Polish Transplantation Society – NanOX Technology at the Centre of Discussions on the Future of Organ Perfusion

The 17th Congress of the Polish Transplantation Society took place in Warsaw on 10–12 September 2026, bringing together experts in clinical and e…

NanoSanguis S.A.: Innovative Bioadsorbers Selected for Funding

NanoSanguis S.A., a subsidiary of NanoGroup S.A., has been awarded funding for the implementation of its “Innovative Bioadsorbers” project. The grant amoun…

Auxilius Pharma: Key FDA Feedback Ahead of the IND Submission for AUX-001

Auxilius Pharma S.A., a biotechnology company set to join the NanoGroup, has successfully completed another stage of its regulatory dialogue with the …

First Production-Ready NanOX Recovery Box Devices Completed. Preclinical Studies of NanOX 4 Kidney to Begin Shortly in Barcelona

NanoSanguis has taken delivery of the first two production units of the NanOX Recovery Box. The devices have already been commissioned and tested by the Na…

Media resources

Company logo

logotype.zip (1.27 MB)
Download
pp-thumbnail